TB-500
Insufficient evidence for this compound
Research-only / investigational — not FDA approved
Investigational; no FDA-approved drug label is established for this entry. Source: FDA: safety concerns for nominated peptide substances
What it is
A fragment of thymosin beta-4, distinct from the full-length peptide. Source: FDA: safety concerns for nominated peptide substances
What it has been studied for
FDA reports no identified human exposure data for this fragment; results for full-length thymosin beta-4 cannot be assumed to apply. Source: FDA: safety concerns for nominated peptide substances
Mechanism
A clinical mechanism for this fragment is not established in the cited source. Source: FDA: safety concerns for nominated peptide substances
Documented dosing
No applicable general-use human dose range, frequency or cycle is documented here. Numbers from other routes, formulations or conditions are not interchangeable.
Pairings & cautions
No evidence-based peptide pairing is specified in this entry.
FDA identifies unresolved safety concerns for this substance. Source: FDA: safety concerns for nominated peptide substances
These are selected considerations, not a complete safety review. Discuss the full source and your medications with your prescriber.
Sources
- FDA: safety concerns for nominated peptide substances · Clinical / regulatory reference
- FDA: safety concerns for nominated peptide substances · Clinical / regulatory reference